Sign in
  1. Home
  2. Companies
  3. Meridian Bioscience
  4. Financial Statements
  5. Income Statement
Meridian Bioscience logo
Meridian Bioscience VIVO
report update icon

Quarterly report 2023-Q1
added 05-16-2026

Meridian Bioscience Income Statement 2022-2007 | VIVO

Brief overview of revenue and earnings at Meridian Bioscience

The conclusions below are based on five years of reported results. The revenue attributed to Meridian Bioscience moved from 52.3 million dollars to 333 million dollars between the two endpoints. The five-year change reached +537%, while CAGR stood at 44.8%. The annual growth rate indicates an exceptionally strong top-line trend.

The gross result shifted from 32 million dollars to 188 million dollars, or +488.4%. Direct costs grew more slowly than revenue and improved the economics of sales. The gross margin was 61.2% at the start and 56.6% at the end. The margin decline reflects a less favorable sales-and-cost structure.

Over the period, EBITDA shifted from 46.5 million dollars to 70.9 million dollars, a change of +52.6%. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from 88.9% to 21.3%. The business retained less EBITDA from each unit of revenue.

The net result moved from 6.3 million dollars to 42.5 million dollars, or +573.7%. Net income grew faster than revenue, indicating improved overall efficiency.

The market value of the business moved from $563 million to $1.4 billion, or +145.9%. Market value lagged the financial performance.

Summary assessment

The figures do not all move in the same direction. Key strengths include improving net profitability and a larger revenue base. The main areas of concern are a declining EBITDA margin and weaker gross profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Meridian Bioscience

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Market Cap

 1.38 B 882 M 801 M 416 M 724 M 563 M 681 M 751 M 573 M 886 M 650 M 575 M - - - -

Shares

 43.6 M 43.3 M 42.9 M 42.6 M 42.3 M 42.2 M 42 M 41.7 M 41.5 M 41.2 M 41.1 M 40.7 M 40.5 M 40.4 M 40.1 M -

Historical Prices

 31.8 20.4 18.7 9.77 17.1 13.3 16.2 18 13.8 21.5 15.8 14.1

Net Income

 42.5 M 71.4 M 46.2 M 24.4 M 8.11 M 6.3 M 6.28 M 8.89 M 7.9 M 7.43 M 8.47 M 6.58 M 6.02 M 8.92 M 30.2 M -

Revenue

 333 M 318 M 254 M 201 M 51.5 M 52.3 M 46.8 M 195 M 189 M 189 M 174 M 160 M - - - -

Cost of Revenue

 145 M 117 M 97.4 M 82.3 M 82.5 M 76.5 M 68.9 M - - - - - - - - -

Gross Profit

 188 M 201 M 156 M 119 M 31.8 M 32 M 29 M 31.6 M 29.2 M 28 M 28.8 M 24.5 M 23.5 M 25.4 M 86.5 M -

Operating Income

 54.4 M 93 M 61.3 M 32.7 M 31.6 M 37.4 M 51.4 M 56.1 M 52.4 M 57.3 M 49.3 M 40 M 41.1 M 48.8 M 44.4 M -

Interest Expense

 1.19 M 1.88 M 2.63 M 1.94 M 1.52 M 1.64 M 897 K -1.02 M -309 K 4 K 378 K 352 K 138 K 88 K 109 K -

EBITDA

 70.9 M 108 M 74.9 M 42.7 M 40.3 M 46.5 M 59.1 M 62.7 M 59.7 M 64.5 M 55.9 M 45.9 M 45.8 M 53.1 M 47.2 M -

Operating Expenses

 134 M 108 M 94.9 M 86 M 99.4 M 86.9 M 75.8 M 65.8 M 64.9 M 63.7 M 59.8 M 58.4 M 47.6 M 43.7 M 42.1 M -

General and Administrative Expenses

 57.1 M 49.5 M 44.3 M 34 M 35.8 M 31.1 M 29.4 M 27.6 M 27.4 M 30.5 M 26.4 M 24.9 M 19.7 M 17.1 M 17.2 M -

All numbers in USD currency

Quarterly Income Statement Meridian Bioscience

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3

Shares

 43.9 M 43.9 M 43.6 M 43.5 M 43.4 M 43.4 M 43.3 M 43.2 M 43.1 M 43.1 M 42.8 M 42.8 M 42.8 M 42.8 M 42.6 M 42.5 M 42.4 M 42.4 M 42.3 M 42.3 M 42.3 M 42.3 M 42.2 M 42.2 M 42.2 M 42.2 M 42.1 M 42.1 M 41.9 M 41.9 M 41.7 M 41.7 M 41.6 M 41.6 M 41.5 M 41.5 M 41.4 M 41.4 M 41.3 M 41.3 M 41.1 M 41.1 M 41.1 M 41.1 M 41.1 M 41.1 M 40.7 M 40.7 M 40.6 M 40.5 M

Net Income

 -29.8 M -29.8 M -7.34 M 28.8 M 15.3 M 15.3 M 11.7 M 26.3 M 26.8 M 26.8 M 27.5 M 9.36 M 2.83 M 2.83 M 5.08 M 7.09 M 8.11 M 8.11 M 6.82 M 5.29 M 6.3 M 6.3 M 240 K 9.31 M 6.28 M 6.28 M 8.75 M 9.09 M 8.89 M 8.89 M 9.1 M 10.1 M 7.9 M 7.9 M 8.84 M 10.3 M 7.43 M 7.43 M 10.2 M 10.2 M 8.47 M 8.47 M 8.59 M 9.63 M 6.58 M 6.58 M 6.84 M 7.26 M 6.02 M 6.42 M

Revenue

 56.9 M 56.9 M 67.8 M 111 M 88.3 M 88.3 M 63.5 M 85.3 M 92.9 M 92.9 M 84.8 M 57.3 M 47.4 M 47.4 M 48.4 M 50.2 M 51.5 M 51.5 M 51.7 M 51.7 M 56.5 M 52.3 M 49.7 M 50.1 M 54.1 M 46.8 M 47 M 50.7 M 46.8 M 47.2 M 47.1 M 48.2 M 47.2 M 48 M 46.7 M 47.2 M 48 M 44.8 M 49 M 47.1 M 44.8 M 45.4 M 43.5 M 41.9 M 45.4 M 40.1 M 41.3 M 40.1 M 40.3 M -

Cost of Revenue

 25.4 M 25.4 M 31 M 42.8 M 39.2 M 39.2 M 26.4 M 27.5 M 31.4 M 31.4 M 28.9 M 22.8 M 20 M 19.8 M 20.2 M 20.9 M 19.9 M 19.9 M 19.8 M 19.8 M 19.9 M 20.3 M 57.4 M 19 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

 31.5 M 31.5 M 36.7 M 68.5 M 49.2 M 49.2 M 37.1 M 57.8 M 61.5 M 61.5 M 55.9 M 34.5 M 27.4 M 27.7 M 28.3 M 29.3 M 31.6 M 31.8 M 32 M 34.6 M 31.8 M 32 M 31.2 M 33.5 M 29.4 M 29 M 32.9 M 33.6 M 31.6 M 31.6 M 30.3 M 32.5 M 29.2 M 29.2 M 29.2 M 31.6 M 28 M 28 M 30.6 M 30.7 M 28.8 M 28.8 M 27.6 M 29.8 M 24.7 M 24.5 M 25.4 M 26.3 M 23.6 M 21.7 M

Operating Income

 -28.1 M -28.1 M -6.68 M 36.1 M 20.3 M 20.3 M 15.7 M 34.2 M 34.7 M 34.7 M 34.7 M 11.8 M 5.39 M 5.39 M 6.46 M 9.84 M 10.6 M 10.6 M 8.74 M 7.68 M 8.06 M 8.06 M 4.3 M 14.2 M 10.1 M 10.1 M 13.7 M 15.2 M 13.6 M 13.6 M 14.4 M 15.7 M 12.7 M 12.7 M 13.1 M 15.7 M 11.6 M 11.6 M 15.7 M 15.3 M 13.1 M 13.1 M 12.6 M 14.8 M 9.8 M 9.8 M 10.1 M 11 M 9.09 M 9.78 M

Interest Expense

 148 K 148 K 256 K 341 K 372 K 372 K 444 K 472 K 534 K 534 K 703 K 532 K 767 K 767 K 448 K 347 K 363 K 363 K 375 K 379 K 395 K 395 K 407 K 408 K 423 K 423 K 427 K 43 K 96 K 96 K -99 K -211 K -582 K -582 K -257 K -28 K -220 K -220 K -160 K 257 K 128 K 128 K 31 K -43 K 316 K 316 K 36 K 118 K 203 K -9 K

EBITDA

 -26.5 M -26.5 M -1.67 M 39.5 M 22 M 22 M 20.4 M 37.3 M 36.2 M 36.2 M 38.4 M 14.2 M 6.61 M 6.61 M 10.4 M 12.4 M 11.8 M 11.8 M 12.1 M 9.91 M 9.21 M 9.21 M 7.56 M 16.3 M 11.2 M 11.2 M 16.6 M 16.9 M 14.5 M 14.5 M 17 M 17.6 M 13.6 M 13.6 M 15.8 M 17.4 M 12.5 M 12.5 M 18.2 M 16.9 M 13.9 M 13.9 M 15.3 M 16.6 M 10.7 M 10.7 M 12.7 M 12.7 M 9.94 M 12.1 M

Operating Expenses

 59.6 M 59.6 M 43.4 M 32.3 M 28.9 M 28.9 M 21.4 M 23.6 M 26.9 M 26.9 M 21.2 M 22.7 M 22 M 22.3 M 21.8 M 19.5 M 21 M 21 M 23.2 M 26.9 M 23.7 M 23.9 M 26.9 M 19.3 M 19.4 M 19 M 19.2 M 18.4 M 18 M 18 M 15.9 M 16.8 M 16.6 M 16.6 M 16.1 M 15.9 M 16.4 M 16.4 M 14.9 M 15.5 M 15.7 M 15.7 M 15 M 14.9 M 14.9 M 14.7 M 15.3 M 15.3 M 14.5 M -

General and Administrative Expenses

 11.1 M 11.1 M 13.1 M 18.6 M 14.7 M 14.7 M 12 M 12.9 M 11.9 M 11.9 M 12.4 M 10.5 M 8.76 M 8.98 M 8 M 7.39 M 8.9 M 8.9 M 8.38 M 9.11 M 8.9 M 9.2 M 8.47 M 7.43 M 8.45 M 7.74 M 7.54 M 6.88 M 8.17 M 8.17 M 6.54 M 6.94 M 7.38 M 7.38 M 6.72 M 6.28 M 7.55 M 7.55 M 6.78 M 7.21 M 7.5 M 7.5 M 6.16 M 6.43 M 6.64 M 6.64 M 6.44 M 5.64 M 6.52 M 4.87 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Meridian Bioscience (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
 		- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
 		$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
 		$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
 		$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
 		- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
 		$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
 		$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
 		$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
 		- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
 		$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
 		- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
 		- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
 		- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
 		- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
 		$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
 		- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
 		- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
 		- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
 		$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
 		$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
 		- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
 		- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
 		$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
 		$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
 		$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
 		$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
 		$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
 		$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
 		$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
 		- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
 		- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
 		- - $ 4.46 B usaUSA